Fund managers have always found it harder to outperform in the US than in any other market, which is why so many have chosen to invest via passive funds and exchange traded funds.
The US market accounts for well over half of the MSCI World index, but the intensity of competition makes it hard for anyone consistently to gain an edge. In addition, the largest companies have outperformed in recent years, yet fund managers nearly always tilt their portfolios away from the giants to allow them to invest more in companies that have only a tiny weight in the S&P 500.
An exception to the rule
Still, one fund stands out. Since Tim Parton and Jonathan Simon were appointed co-managers of the £1.5bn JPMorgan American Investment Trust (LSE: JAM) in 2019, they have outperformed the S&P 500 by 3% per year.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The duo manage a portfolio of just 40 stocks, with Parton running the half made up of underappreciated “growth” opportunities, and Simon the half made up of “value” stocks with a “durable franchise”.
Parton avoids stocks without established businesses or visible cash flow. Simon avoids those that are simply cheap. Value includes Bristol Myers and Abbvie in the healthcare sector and Berkshire Hathaway in the financials.
Growth is underweight in technology, but includes agricultural machinery company John Deere and Intuitive Surgical in healthcare. Both keep an eye on the benchmark so Apple is held at a below-benchmark weighting. There’s Mastercard, but not Visa; ConocoPhillips, but not ExxonMobil.
Tesla was recently bought back after being sold last year. JPMorgan Chase cannot be held, but there is a sizeable holding in Bank of America. The value is added in lesser-known companies such as Loews (hotels, insurance, energy and packaging), Weyerhaeuser (the largest listed timber company), Martin Marietta (building products) and Packaging Corporation of America.
Some 5% of the portfolio is invested in smaller companies by a separate team, though this has held performance back recently. The equivalent of 6.5% of net assets is borrowed to enhanced performance.
The overall portfolio valuation is similar to that of the S&P 500, and the average market value of the holding is only 10% less, at $552bn. This makes the solid performance achieved while carefully controlling the risk relative to the S&P500 all the more creditable.
The trust deserves to be a core holding in almost any portfolio, particularly since UK investors tend to be underexposed to the US market as a default consequence of a high exposure to the UK. Those who relaxed about their avoidance of the “expensive” US market when the UK index at last started to outperform earlier this year need to start worrying.
The UK’s relative recovery is starting to look like a flash in the pan due to the poor performance of its financial sector and the carpet-bagging stocks from emerging markets.
American alternatives
There are two other investment trusts focused on North America: Baillie Gifford US Growth (LSE: USA) and Pershing Square (LSE: PSH). Both have performed well in the last three years, but JAM gives the broadest exposure to the US market. US Growth has performed well when growth shares are in favour, but not when value is outperforming. Pershing Square is highly focused – it has just 11 holdings, of which two are below 1% of the portfolio – and often activist in its approach, seeking to bring about change in the companies in which it invests.
However, that is not the case with two recent investments in Universal Music (25% of the portfolio) and Netflix (11%), the theses for which look highly promising. With a three-year return of 124%, PSH’s 30% discount to net-asset-value compared with 3% for JAM can only be described as bizarre.
-
MoneyWeek news quiz: Which G7 nation has the most generous state pension?The chancellor “set the context” for the Budget on 26 November this week, and November's Premium Bonds winners were confirmed. The state pension also made headlines. How closely have you been following the news?
-
Have a will? It may not be enough to secure your wishes – here’s what you need tooIncorporating a letter of wishes into your estate planning can provide a unique opportunity to personally guide your loved ones on your final wishes for them and you. We explain how a letter of wishes works.
-
Japan is still rising to new highs – here's how to investOpinion Political ructions in Japan are no obstacle to gains, and the return of inflation may even benefit stocks, says Max King. What is Japan doing right?
-
Investors need to get ready for an age of uncertainty and upheavalTectonic geopolitical and economic shifts are underway. Investors need to consider a range of tools when positioning portfolios to accommodate these changes
-
The MoneyWeek Wealth Summit 2025: how to invest for a volatile eraMoneyWeek's 25th birthday conference’s agenda offers investors a wide array of compelling themes
-
How to invest in undervalued gold minersThe surge in gold and other precious metals has transformed the economics of the companies that mine them. Investors should cash in, says Rupert Hargreaves
-
Who is Rob Granieri, the mysterious billionaire leader of Jane Street?Profits at Jane Street have exploded, throwing billionaire Rob Granieri into the limelight. But it’s not just the firm’s success that is prompting scrutiny
-
Beware the bubble in bitcoin treasury companiesBitcoin treasury companies are no longer coining it. Short this one, says Matthew Partridge
-
New faces don’t solve old problems – why strategy also matters when it comes to investment trustsOpinion Changing managers often fails to boost a trust’s performance, says Max King
-
Are venture-capital trusts worth investing in?Venture-capital trusts are a tax-efficient way to invest in early-stage companies. But are they worth the risk?
